{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:00:51Z","timestamp":1789952451223,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004367","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000}}],"reference-count":48,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004367.pub2","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T11:09:17Z","timestamp":1233659357000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Olanzapine in long-term treatment for bipolar disorder"],"prefix":"10.1002","volume":"2010","author":[{"given":"Andrea","family":"Cipriani","sequence":"first","affiliation":[{"name":"University of Verona; Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology; Policlinico \"G.B.Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Rendell","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Geddes","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"10.1002\/14651858.CD004367.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.jcp.0000132344.35713.5f","article-title":"Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder","volume":"24","author":"Altamura","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Tohen M Ketter TA Zarate CA Suppes T Frye M Altshuler L Zajecka J Schuh LM Risser RC Brown E Baker RW Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study Am J Psychiatry 2003 1263 71","DOI":"10.1176\/appi.ajp.160.7.1263"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Tohen M Chengappa KN Suppes T Baker RW Zarate CA Bowden CL Sachs GS Kupfer DJ Ghaemi SN Feldman PD Risser RC Evans AR Calabrese JR Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone British Journal of Psychiatry 2004 337 45","DOI":"10.1192\/bjp.184.4.337"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Tohen M Greil W Calabrese JR Sachs GS Yatham LN Oerlinghausen BM Koukopoulos A Cassano GB Grunze H Licht RW Dell'Osso L Evans AR Risser R Baker RW Crane H Dossenbach MR Bowden CL Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial American Journal of Psychiatry 2005 1281 90","DOI":"10.1176\/appi.ajp.162.7.1281"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0006|cit6","first-page":"33","article-title":"New treatments for bipolar disorder: the role of atypical neuroleptic agents","volume":"61 Suppl 14","author":"Ghaemi","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0007|cit7","first-page":"19","article-title":"An ever-increasing pharmacopoeia for the management of patients with bipolar disorder","volume":"61 Suppl 13","author":"Nemeroff","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0008|cit8","first-page":"38","article-title":"Antipsychotic agents and bipolar disorder","volume":"59 Suppl 1","author":"Tohen","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0009|cit9","first-page":"940","article-title":"Use of atypical antipsychotics in mood disorders","volume":"2","author":"Weizman","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0010|cit10","first-page":"10","article-title":"The role of novel antipsychotics in bipolar disorders","volume":"63 Suppl 3","author":"Yatham","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1034\/j.1399-5618.2002.01184.x","article-title":"Are patients with bipolar affective disorder socially disadvantaged? A comparison with a control group","volume":"4","author":"Abood","year":"2002","journal-title":"Bipolar Disorders"},{"issue":"11","key":"10.1002\/14651858.CD004367.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD004367.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0006-3223(00)00909-4","article-title":"Historical perspectives and natural history of bipolar disorder","volume":"48","author":"Angst","year":"2000","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD004367.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0165-0327(01)00377-9","article-title":"Mortality of patients with mood disorders: follow-up over 34-38 years","volume":"68","author":"Angst","year":"2002","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0015|cit15","volume-title":"Diagnostic and statistical manual of mental disorders. DSM-IV","author":"American Psychiatric Association","year":"1994"},{"issue":"7-8","key":"10.1002\/14651858.CD004367.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1345\/aph.19327","article-title":"Olanzapine-induced glucose dysregulation","volume":"34","author":"Bettinger","year":"2000","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0017|cit17","first-page":"1","article-title":"Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials","volume":"Jul 17 [Epub ah","author":"Beynon","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD004367.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","article-title":"A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group","volume":"57","author":"Bowden","year":"2000","journal-title":"Archieves of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD004367.pub2-BIB0019|cit19","article-title":"Lithium for maintenance treatment of mood disorders","author":"Burgess","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1176\/appi.ajp.162.10.1805","article-title":"Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials","volume":"162","author":"Cipriani","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004367.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0924-9338(00)00515-0","article-title":"Improvement of tardive dyskinesia in a bipolar patient with olanzapine","volume":"15","author":"Esel","year":"2000","journal-title":"European Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004367.pub2-BIB0023|cit23","first-page":"73","article-title":"The Expert Consensus Guidelines for treating depression in bipolar disorder","volume":"59","author":"Frances","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004367.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0327(00)00299-8","article-title":"The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology and treatment issues","volume":"68","author":"Freeman","year":"2002","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0025|cit25","volume-title":"Manic-depressive illness","author":"Goodwin","year":"1990"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1192\/bjp.170.3.205","article-title":"Suicide as an outcome for mental disorders: a mate-analysis","volume":"170","author":"Harris","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004367.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1440-1819.2002.01050.x","article-title":"Can olanzapine be implicated in causing serotonin syndrome?","volume":"56","author":"Haslett","year":"2002","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0028|cit28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0","author":"Higgins","year":"[updated February 2008]"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD004367.pub2-BIB0029|cit29","first-page":"13S","article-title":"Carbamazepine and valproate in the maintenance treatment of bipolar disorder","volume":"63","author":"Keck","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0030|cit30","first-page":"647","article-title":"Relationship between drug company funding and outcomes of clinical psychiatric research","volume":"361","author":"Kelly","year":"2006","journal-title":"Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004367.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1017\/S0033291797005333","article-title":"The epidemiology of DSM-III-R bipolar I disorder in a general population survey","volume":"27","author":"Kessler","year":"1997","journal-title":"Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004367.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/j.1440-1614.2006.01820.x","article-title":"Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia","volume":"40","author":"Lee","year":"2006","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD004367.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0924-977X(00)00132-2","article-title":"Manic symptoms induced by olanzapine","volume":"11","author":"Lykouras","year":"2001","journal-title":"European Neuropsychipharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004367.pub2-BIB0034|cit34","article-title":"Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder","author":"Macritchie","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD004367.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0006-3223(00)00961-6","article-title":"Pharmacologic agents for the treatment of acute bipolar mania","volume":"48","author":"McElroy","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0036|cit36","first-page":"1893","article-title":"Central Nervous System agents","volume-title":"AHFS drug information","author":"McEvoy","year":"1999"},{"issue":"9063","key":"10.1002\/14651858.CD004367.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","article-title":"Global mortality, disability and contribution of risk factors: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0038|cit38","first-page":"131","article-title":"Genetics","volume-title":"Handbook of Affective Disorders","author":"Nurnberg","year":"1992"},{"issue":"6","key":"10.1002\/14651858.CD004367.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1176\/appi.psy.42.6.528","article-title":"Olanzapine usage associated with neuroleptic malignant syndrome","volume":"42","author":"Philibert","year":"2001","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1002\/14651858.CD004367.pub2-BIB0040|cit40","article-title":"Olanzapine alone or in combination for acute mania","author":"Rendell","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004367.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1345\/aph.10178","article-title":"Olanzapine-induced hyperglycemic nonketonic coma","volume":"35","author":"Roefaro","year":"2001","journal-title":"The Annals of Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD004367.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4088\/JCP.v63n0502","article-title":"Nonaherence with mood stabilizers: prevalence and predictors","volume":"65","author":"Scott","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD004367.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1176\/ps.50.10.1303","article-title":"Health care utilization and costs among patients treated for bipolar disorder in an insured population","volume":"50","author":"Simon","year":"1999","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11390","article-title":"A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder","volume":"11","author":"Soares-Weiser","year":"2007","journal-title":"Health Technology Assessment"},{"issue":"12","key":"10.1002\/14651858.CD004367.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archpsyc.1991.01810360046007","article-title":"Risk of recurrence following discontinuation of lithium treatment in bipolar disorder","volume":"48","author":"Suppes","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially non-responsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD004367.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1192\/bjp.bp.107.043133","article-title":"Lithium in mood disorders: increasing evidence base, declining use?","volume":"191","author":"Young","year":"2007","journal-title":"British Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004367.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:07:46Z","timestamp":1789949266000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004367.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004367.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}